Literature DB >> 27896437

[Inflammatory myopathies].

Britta Maurer1.   

Abstract

Inflammatory myopathies comprise heterogeneous, often multisystemic autoimmune diseases with muscle involvement as a common feature. The prognosis largely depends on a timely diagnosis and initiation of therapy. Given the complexity of these rare diseases, when an inflammatory myopathy is suspected patients should be referred to an expert center with established algorithms for the diagnostic work-up. The differential diagnostic exclusion of myositis mimics should ideally be carried out in close collaboration with neurologists and neuropathologists. The choice of immunosuppressive treatment should primarily depend on disease severity and organ involvement but age and comorbidities also have to be taken into account.

Entities:  

Keywords:  Autoimmune diseases; Diagnosis; Immunosuppressants; Skeletal muscles; Therapy

Mesh:

Substances:

Year:  2017        PMID: 27896437     DOI: 10.1007/s00393-016-0233-9

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  21 in total

1.  Developing standardised treatment for adults with myositis and different phenotypes: an international survey of current prescribing preferences.

Authors:  Sarah Tansley; Gavin Shaddick; Lisa Christopher-Stine; Charlotte Sharp; Lyubomir Dourmishev; Britta Maurer; Hector Chinoy; Neil McHugh
Journal:  Clin Exp Rheumatol       Date:  2016-05-31       Impact factor: 4.473

2.  Isolated elevation of aldolase in the serum of myositis patients: a potential biomarker of damaged early regenerating muscle cells.

Authors:  Livia Casciola-Rosen; John C Hall; Andrew L Mammen; Lisa Christopher-Stine; Antony Rosen
Journal:  Clin Exp Rheumatol       Date:  2012-08-29       Impact factor: 4.473

Review 3.  Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis.

Authors:  Patrick A Gordon; John B Winer; Jessica E Hoogendijk; Ernest H S Choy
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

4.  Mortality and its predominant causes in a large cohort of patients with biopsy-determined inflammatory myositis.

Authors:  V Limaye; P Hakendorf; R J Woodman; P Blumbergs; P Roberts-Thomson
Journal:  Intern Med J       Date:  2012-02       Impact factor: 2.048

Review 5.  Morbidity and mortality in adult polymyositis and dermatomyositis.

Authors:  Isabelle Marie
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

Review 6.  Role of MRI in diagnosis and management of idiopathic inflammatory myopathies.

Authors:  Britta Maurer; Ulrich A Walker
Journal:  Curr Rheumatol Rep       Date:  2015-11       Impact factor: 4.592

Review 7.  Toxic and drug-induced myopathies.

Authors:  M C Dalakas
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-08       Impact factor: 10.154

Review 8.  Myositis mimics: how to recognize them.

Authors:  David Hilton-Jones
Journal:  Curr Opin Rheumatol       Date:  2014-11       Impact factor: 5.006

Review 9.  Therapeutic advances in myositis.

Authors:  Rohit Aggarwal; Chester V Oddis
Journal:  Curr Opin Rheumatol       Date:  2012-11       Impact factor: 5.006

Review 10.  Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken.

Authors:  Olivier Benveniste; Werner Stenzel; David Hilton-Jones; Marco Sandri; Olivier Boyer; Baziel G M van Engelen
Journal:  Acta Neuropathol       Date:  2015-01-13       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.